Shire US Inc. has been accused of paying off generic rivals in order to delay the availability of cheaper versions of Adderall, an attention deficit hyperactivity disorder (ADHD) drug. Now, consumers are defending their bid for class certification, arguing that, under the drugmaker’s logic, it would be impossible to ever certify a consumer class action over pharmaceuticals. Consumers have been fighting to secure class status since June, claiming that Shire issued pay-for-delay settlements to stave off competition.

The plaintiffs have filed suit under the Florida Deceptive and Unfair Practices Act, as well as state and federal antitrust law. To read the full article, please click here.